Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors

Diabetes mellitus is a chronic metabolic disease affected a wide range of population all over the world and leads to development of many severe long term complications. Aldose reductase (AR) is the enzyme considered to play a key role in the development of secondary diabetic complications via polyol pathway. AR inhibition has been proposed as a strategy to prevent and delayed such complications. 2,4-thiazolidinedione derivatives being isosteres of hydantoin, emerged as potential AR inhibitors with antidiabetic activity. Therefore, we have designed novel arylidene-2, 4-thiazolidinediones as AR inhibitors using molecular docking technique. Mol-dock score along with re-rank score was the criteria for measuring the affinity of STMG-(1-40) with the AR enzymes. Result of present study will provide a new guideline for the further design of novel potent inhibitors of AR in the management of diabetes along with its complications.